From the outside, orthopedics to oncology to hepatology reads as breadth. Justin Coffeen describes each transition as humbling, and is specific about which parts of the job carried over and which did not.
What this episode covers
- Why the clinical content change into oncology was larger than expected
- The three things that did not change across any transition
- Good Clinical Practice as portable methodology rather than a certificate
- Why claiming expertise in every area is the wrong account of a multi-area career
Two lists worth keeping separate
Every therapeutic area move produces two inventories. One is what the professional already has: protocol discipline, documentation habits, escalation instincts, and the ability to hold a careful conversation with someone about their symptoms. The other is what they do not yet have, which is the disease.
Justin Coffeen was explicit about that division from the start of each transition. Knowing which list an item belongs on is what prevents a research professional from either freezing or overclaiming.
The failure he describes avoiding is the second one. A coordinator who performs familiarity with an unfamiliar indication produces confident answers to questions they cannot actually answer, and in research those answers attach to participants.
Stakes change the texture of the work
Oncology participants are frequently managing a diagnosis that has reorganised their life, and often arrive at a trial because other options have not worked. The consent conversation carries different weight. The adverse event profile is more complex and the protocols ask for more tracking.
None of that is a reason to hesitate, but pretending the register is the same as an orthopedic study is its own kind of error.
What a multi-area career actually demonstrates
The reading Justin Coffeen pushes back on is that someone who has worked three indications became an expert in three diseases. His account is narrower and more useful. The expertise is in the research process, which is genuinely portable, and the disease knowledge is a standing obligation that never finishes.
That framing sets a different bar for adaptability. It is not a claim about how quickly someone learns. It is a claim about how honestly they track what they have not learned yet.
Transcript
I want to be honest about something that doesn’t get talked about much, which is what it actually feels like to move from one therapeutic area to another in clinical research. Because from the outside, if you list orthopedics, oncology, and hepatology on a resume, it looks like breadth. From the inside, each transition was genuinely humbling.
When I moved into oncology from orthopedics, the clinical content change was significant. The patient population is different. The stakes feel different in a specific way, meaning the people in those trials are often dealing with something that has really reorganized their whole life. The protocols are more demanding in terms of what they’re asking you to track. The adverse event profile is more complex.
And here’s what I remember thinking pretty early in that transition: I don’t know enough about this disease area to pretend otherwise, but I do know how to run a protocol compliantly, I do know how to have a careful conversation with a participant about their symptoms, and I do know how to escalate appropriately when something isn’t clear. Those things didn’t change.
That’s really the argument I’d make for GCP as more than a certification. When you truly understand the framework, when it’s not just rules you’ve memorized but an actual approach to how research should be conducted, it’s portable. You can carry it into a new disease area and apply it while you’re still building the disease-specific knowledge.
The move to hepatology was a similar experience. Different patient population, different laboratory parameters I needed to learn, different clinical language. But I could have the right conversations from day one because the communication skills, the documentation habits, the protocol discipline, those were already there.
I think the mistake people make when they see a career that’s crossed multiple therapeutic areas is assuming the person became an expert in each one. That’s not quite it. The expertise is in the research process itself. The disease content is what requires ongoing learning, and that’s fine. That’s supposed to keep happening.
I’m based in Lakewood Ranch, Florida, and I think about this a lot, what it means to be genuinely adaptable in research versus just claiming it.